5-HT imaging in depression: Version 1.0
Research type
Research Study
Full title
Evaluation of serotonergic neurotransmission in depression and Parkinson’s disease
IRAS ID
233767
Contact name
Eugenii Rabiner
Contact email
Sponsor organisation
Imanova Limited
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
Study Title- Evaluation of serotonergic neurotransmission in depression and Parkinson’s disease:
The human brain works by exchanging chemical messengers (neurotransmitters) between specific cell-proteins (receptors).
Depressive disorders have been attributed to insufficient levels of the neurotransmitter- serotonin (5-HT)
This study aims to look at the serotonin release capacity in regions of interest in the brain of patients with depressive disorder, Parkinson's disease and gender-age matched healthy volunteers
We will use the PET ligand [11C]cimbi-36 to study the density of 5-HT2C in the frontal cortex region of the brain
We will study patients with major depressive disorder(MDD) Parkinson's disease (PD) and healthy volunteers (HV) on two occasions. Once at baseline, and the second time after a dose of oral dexamphetamine
The data will provide information that could lead to further investigate the differences in brain 5-HT release in patients with 5-HT deficits
REC name
East of England - Cambridge East Research Ethics Committee
REC reference
17/EE/0484
Date of REC Opinion
9 Feb 2018
REC opinion
Further Information Favourable Opinion